265 related articles for article (PubMed ID: 25599163)
21. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia.
Devillier R; Crocchiolo R; Etienne A; Prebet T; Charbonnier A; Fürst S; El-Cheikh J; D'Incan E; Rey J; Faucher C; Blaise D; Vey N
Leuk Lymphoma; 2013 Jun; 54(6):1228-34. PubMed ID: 23082952
[TBL] [Abstract][Full Text] [Related]
22. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
23. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
24. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
[TBL] [Abstract][Full Text] [Related]
25. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A; Bruns I; Kröger N; Platzbecker U; Lind J; Zohren F; Fenk R; Germing U; Schröder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2010 May; 45(5):872-6. PubMed ID: 19820729
[TBL] [Abstract][Full Text] [Related]
26. Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome.
Choi Y; Kim SD; Park YH; Lee JS; Kim DY; Lee JH; Lee KH; Seol M; Lee YS; Kang YA; Jeon M; Jung AR; Lee JH
Acta Haematol; 2015; 133(2):183-92. PubMed ID: 25323649
[TBL] [Abstract][Full Text] [Related]
27. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
[TBL] [Abstract][Full Text] [Related]
28. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Koren-Michowitz M; Maayan H; Apel A; Shem-Tov N; Yerushalmi R; Volchek Y; Avigdor A; Shimoni A; Nagler A
Ann Hematol; 2015 Mar; 94(3):375-8. PubMed ID: 25307457
[TBL] [Abstract][Full Text] [Related]
29. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
31. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
Lazzarotto D; Candoni A; Filì C; Forghieri F; Pagano L; Busca A; Spinosa G; Zannier ME; Simeone E; Isola M; Borlenghi E; Melillo L; Mosna F; Lessi F; Fanin R
Leuk Res; 2017 Feb; 53():74-81. PubMed ID: 28056398
[TBL] [Abstract][Full Text] [Related]
34. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K
Bone Marrow Transplant; 2007 Dec; 40(11):1027-32. PubMed ID: 17846595
[TBL] [Abstract][Full Text] [Related]
36. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
[TBL] [Abstract][Full Text] [Related]
37. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
39. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
[TBL] [Abstract][Full Text] [Related]
40. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
